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Abstract: Advancements in the understanding of tumor immunology in urothelial carcinoma (UC)
have led to U.S Food and Drug Administration (FDA) approval of five novel anti-programmed
cell death protein-1/ligand 1 (PD-1/L1) checkpoint inhibitors. In 2017, the anti-PD-L1 antibody
atezolizumab and the anti-PD-1 antibody pembrolizumab gained approval for use in cisplatin-
ineligible patients with locally advanced and metastatic UC. These approvals were based on single-arm
trials, IMvigor210 (atezolizumab) and KEYNOTE-052 (pembrolizumab). Since then, additional
checkpoint inhibitors, including avelumab, durvalumab, and nivolumab, have gained approval.
Preliminary results suggest additional benefits with combinations of these agents in both first- and
subsequent-line therapies, inferring a paradigm shift in the future treatment approach in advanced
UC. Ongoing clinical trials will investigate how to utilize predictive biomarkers for optimal patient
selection and to incorporate immunotherapy into earlier lines of multimodal treatment. In this
comprehensive review, we summarize the evidence supporting the use of checkpoint inhibitors for
patients with UC, and highlight ongoing clinical trials that are investigating novel combinations of
immunotherapy in various disease settings.
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1. Introduction
Urothelial carcinoma (UC) of the urinary tract is the fourth most common type of malignancy
worldwide [1]. Tobacco smoking is the most common risk factor and is responsible for 50% of
all UCs. Other risk factors include pelvic radiation for other malignancies, genetic predisposition,
and occupational exposure to carcinogens, including polycyclic aromatic hydrocarbons, chlorinated
hydrocarbons, and aromatic amines [2].
The urinary bladder is the most common pathologic site of occurrence, followed by the renal
pelvis and the ureter of the upper urinary tract and the urethra of the lower urinary tract. Despite
advancements in the understanding of the underlying pathophysiology of UC, high recurrence rates
in the early stages and ineffective systematic treatments for metastatic and advanced diseases are
drawbacks to significant improvements in the overall prognosis of UC [3].
Recent advancements in the understanding of tumor immunology have opened new horizons
for the management of UC. Knowledge of the biology of the immune system regarding checkpoint
molecule inhibitors has led to the development of novel systemic agents with applications in various
malignancies [4]. These agents have shown positive results in the treatment of locally advanced and
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metastatic UCs and are now being investigated for application in other clinical settings [4]. In this article,
we perform a comprehensive review of contemporary literature to investigate evidence regarding
current chemotherapy and emerging immunotherapy agents, biomarkers for predicting treatment
response, and ongoing clinical trials for UC.
2. Classification of Urothelial Carcinoma
2.1. Histological Subtypes
Transitional cell carcinoma is the most common histological subtype of UC of the urinary bladder,
and variant histology is identified in approximately 10% of all UCs. Accurate identification of variant
histology has important implications for patient management. Unfortunately, variant histology is often
under-recognized or misclassified due to evolving criteria for diagnosis and multiple synchronous
variants that may exist in a single patient [5].
The 2016 World Health Organization classification provides the most updated pathological
category and variant subtypes of UC based on molecular features (Table 1) [6]. Overall, treatment
regimens effective for conventional UC have limited efficacy for variant histology, and patients usually
exhibit an aggressive disease course. Neoadjuvant chemotherapy and subsequent radical cystectomy
are recommended for patients with variant histology. Nevertheless, radical cystectomy is generally
recommended as a first-line treatment due to limited data supporting the efficacy of perioperative
chemotherapy or radiation therapy.
Table 1. Variant subtypes of urothelial carcinoma.
UC with Divergent Differentiation
With squamous cell differentiation
With glandular differentiation
With trophoblastic differentiation
With small-cell carcinoma
UC with deceptively benign histological features
Nested UC (including large nested)
Microcystic UC
Differential diagnosis with metastases or secondary extension to the bladder
Micropapillary UC
Plasmacytoid/signet ring cell/diffuse UC
Sarcomatoid UC (carcinosarcoma)
Giant cell UC
Clear cell (glycogen-rich) UC
UC, lipid-cell variant
Poorly differentiated tumors (undifferentiated carcinoma NOS, osteoclast-rich undifferentiated carcinoma,
undifferentiated carcinoma with rhabdoid features and loss of expression of the SWI/SNF complex
Marked immune cell response
Lymphoepithelioma-like urothelial carcinoma
NOS, not otherwise specified; SWI/SNF, SWItch/sucrose non-fermentable; UC, urothelial carcinoma.
The advancements in pathological diagnosis and understanding of how different histological
variants affect the disease course is changing the paradigm of UC management, especially in regard
to immunotherapy [7,8]. For instance, lymphoepithelioma-like UCs are characterized as harboring
prominent lymphoid stroma that includes T and B lymphocytes, histiocytes, plasma cells, and occasional
neutrophils or eosinophils. Preliminary data has shown that this subset of patients exhibits higher
response rates to immunotherapy than in those with conventional UCs [9,10].
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2.2. mRNA Subtypes
The Cancer Genome Atlas (TCGA) analysis for muscle-invasive bladder cancer allowed the
identification of mRNA subtypes: (1) luminal-papillary, (2) luminal-infiltrated, (3) luminal, (4)
basal/squamous, and (5) neuronal [11]. The classification based on mRNA subtypes has the potential
to be utilized to stratify patients for a specific treatment regimen. For instance, relatively higher
mutational burden and higher antigen load were identified in the MSig1 cluster, characterized by
favorable survival outcomes in this subset of patients. Improved survival observed in these patients
infers the presence of a natural host immune reaction to the high antigen load that may have inhibited
tumor growth and metastasis [11]. Indeed, this presumption warrants confirmation in clinical trials,
preferably involving immune checkpoint inhibitors. Furthermore, the validation of this subtype as
a prognosticator for the response to immunotherapy may support the use of immunotherapy in the
neoadjuvant setting since a higher load of tumor antigens would be present if the primary tumor is
still in-situ.
3. Treatment Strategy of Urothelial Carcinoma of the Urinary Bladder
UC of the urinary bladder is categorized into non-muscle invasive disease (Ta, T1, and Tis),
muscle-invasive disease (≥T2), and metastatic disease, and each clinical spectrum differs in prognosis,
management, and treatment strategy [3]. In general, conventional treatment options for muscle-invasive
or metastatic disease included chemotherapy, radiation therapy, and radical cystectomy [2].
3.1. Muscle-Invasive Disease
Approximately 20% of patients with bladder carcinoma are initially diagnosed with
muscle-invasive disease [12]. Muscle-invasive disease is characterized by malignant infiltration
beyond the basement membrane. The treatment goal is focused on determining whether the bladder
can be preserved without compromising recurrence-free survival, or whether it should be removed to
maximize survival outcome.
For muscle-invasive disease without metastasis, cisplatin-based neoadjuvant chemotherapy is
recommended for patients fit for radical cystectomy. For patients who have not received cisplatin-based
neoadjuvant chemotherapy and have a non-organ confined disease (pT3/T4 and/or N+), adjuvant
cisplatin-based chemotherapy is recommended. For patients who desire to preserve the urinary
bladder, maximal debulking transurethral resection of the tumor and subsequent administration of
adjuvant chemo-radiation therapy could be an option [2].
3.2. Metastatic Disease
Approximately 5% of patients initially present with metastatic disease, and the goal is to prolong
survival without compromising the quality of life. For patients with metastatic disease, cytotoxic
therapy has been the standard treatment of choice during the past half-decade [3,13]. The most common
first-line chemotherapy regimens for cisplatin-eligible patients with locally advanced or metastatic
disease include gemcitabine plus cisplatin (GC) and dose-dense methotrexate, vinblastine, doxorubicin,
and cisplatin (M-VAC), which result in median overall survivals (OS) of 13.8 and 14.8 months,
respectively [14,15]. On the other hand, a significant proportion of patients with advanced disease
are cisplatin-ineligible due to negative prognostic factors such as poor Eastern Cooperative Oncology
Group (ECOG) performance status, old age, impaired renal function, or significant comorbidities.
Second-line chemotherapy or supportive treatment provides significantly less survival benefit, with a
median OS of approximately nine months [16,17].
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4. Chemotherapy for the Treatment of Urothelial Carcinoma
4.1. First-Line Chemotherapy for Cisplatin-Eligible Patients with Urothelial Cancer
Cisplatin-based chemotherapy is the initial regimen of choice for cisplatin-eligible patients with
metastatic UC. The M-VAC regimen has shown a high response rate of 72% for metastatic disease
and has been adopted as the standard front-line treatment [18]. Subsequent clinical trials showed
that cisplatin-based combination regimens were more efficient in comparison to the administration of
single-agent cisplatin [19]. However, the overall therapeutic efficacy of this combination regimen was
hindered by high toxicity and low tolerability. In the early 2000s, the less toxic combination of GC was
accepted as a new standard of care in the palliative setting for patients with advanced UCs.
The GC regimen failed to show a superior prolongation in OS compared to the M-VAC regimen.
However, patients exhibited lower rates of neutropenia, mucositis, and resulting neutropenic fever,
demonstrating that the GC regimen provided a less toxic alternative to M-VAC chemotherapy [20].
Still, only 60% of patients tolerated the first cycle. Compared to the M-VAC regimen, the GC regimen
resulted in a higher prevalence of thrombocytopenia. The addition of paclitaxel to GC (PCG) is a triple
combination that is administered on a three-week schedule. The PCG regimen improved response
rates but failed to provide a statistically significant improvement in OS compared to the one-month
schedule of the GC regimen [21].
4.2. First-Line Chemotherapy for Cisplatin-Ineligible Patients with Urothelial Cancer
Cisplatin-based chemotherapy is the first treatment option for locally advanced or metastatic
disease. However, due to toxicity, the regimen is not well tolerated, and approximately two-thirds of
the patients are ineligible [22]. The criteria for cisplatin ineligibility are ECOG performance status ≥2,
grade ≥2 neuropathy or hearing loss, New York Heart Association classification III heart failure, and
creatine clearance <60 mL/min. Cisplatin-ineligible patients have inferior survival outcomes compared
to those receiving cisplatin. Therefore, the development of alternative therapies is imperative for
this population.
For patients who are ineligible for cisplatin but who are still suitable for combination chemotherapy,
carboplatin-based regimens have a crucial role. Attempts were performed to reduce the toxicity of
chemotherapy by substituting carboplatin for cisplatin. The methotrexate, carboplatin, and vinblastine
(MCAV) regimen were compared with the gemcitabine and carboplatin (GemCarbo) regimen for
cisplatin-ineligible patients in a European Organization for Research and Treatment of Cancer trial [23].
The study population included those with poor kidney function, in addition to ECOG performance
status ≥2 patients. The study showed comparable objective response rates (ORR) and OS rates
between the GemCarbo and MCAV regimens (ORR 36.1% vs. 21.0%, p = 0.08; and OS 9.3 months
vs. 8.1 months, p = 0.64, respectively). Of the two regimens, higher rates of severe acute toxicity
such as renal toxicity, thrombocytopenia, neutropenic fever, and death were noted in the MCAV
regimen compared to the GemCarbo regimen (21.2% vs. 9.3%, respectively). In patients with both
poor performance and kidney function, the ORR decreased to 25% in the GemCarbo regimen and
increased to 27% for the MCAV regimen, while an increase in severe toxicity rates was shown for
both regimens (12.5% for the GemCarbo regimen vs. 27.3% for the MCAV regimen). The feasibility of
triple combination chemotherapy has been studied in patients with renal insufficiency. A regimen
consisting of gemcitabine, carboplatin, and paclitaxel was investigated in patients without a history of
chemotherapy or with only one prior chemotherapy regimen. The trial enrolled patients regardless of
renal function, with a cutoff value of serum creatinine of ≤2.5 mg/dL [24]. The ORR was 43%, with a
median OS of 11 months. Due to the high incidences of neutropenia, this regimen was considered
more toxic compared to conventional doublet-based chemotherapy.
Cancers 2020, 12, 192 5 of 22
5. Immunotherapy for the Treatment of Urothelial Carcinoma
5.1. The Rationale for Immunotherapy in Urothelial Carcinoma
The scope of immunotherapy for cancer patients has broadened tremendously with breakthroughs
in the understanding of the immune system. The objective of immunotherapy is to eliminate cancer cells
by augmenting the interaction between the immune and tumor cells of the host. Clinical applications
of immunotherapy include boosting the immune response with exogenous cytokines, administering
vaccines for tumor-associated antigens, and activating targeted antibodies on the surface proteins
of immune checkpoint molecules [18]. In normal physiology, immune checkpoints suppress the
adaptive immune response to prevent incorrect or prolonged T-cell activation [25]. In this process,
antigen presentation to the T cells by antigen-presenting cells (APCs) is the key component. Several
co-stimulatory or inhibitory proteins that permit T cells to activate the immune process have been
identified. The CD28 protein plays a pivotal role in the stimulation of T cells. The binding of CD28
proteins on T cells to the proteins on APCs causes T-cell proliferation. The T cell inhibition cascade
is activated after cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) is bound to its ligands (B7-1
or B7-2), or when programmed death 1 (PD-1) protein binds to its PD-L1 ligand on the surface of
tumor cells or APCs [25]. Cancer cells may evade the anti-tumor immune response by exploiting these
immune checkpoint pathways and inhibiting the host immune cell (IC) proliferation [26].
Apart from the CTLA-4 and PD-1/PD-L1 pathways, other immune molecules, such as T cell
immunoglobulin mucin-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and the B7 superfamily
(B7-H3, B7-H4) are currently being studied as candidates for future immune checkpoints. As a
regulatory molecule, TIM-3 has a crucial role in innate immune cell-mediated antitumor responses.
Along with PD-L1, TIM-3 is coexpressed by CD8 tumor-infiltrating lymphocytes (TIL), which results
in negative regulation of cytokine secretion [27]. The LAG-3 molecule is located on the surface of the
immune cells and plays a diverse role in T cell regulation. The protein negatively regulates the cellular
proliferation and activation of T cells and has been observed to play a suppressive role in the CD4 and
CD8 immune response [28]. B7-H3 and B7-H4 are part of the B7 costimulatory molecules which can be
found in immune and nonlymphoid cells. The role of B7-H3 in the cancer immune-axis is controversial.
Although the molecule was first characterized as a T cell activator, several studies have shown it may
trigger both upregulation and downregulation of T cell function [29,30].
Evidence from various studies suggests that inhibiting the checkpoint pathway is suitable
for cancers with high somatic mutation rates, which may trigger a high number of tumor-specific
neo-antigens [31,32]. DNA mutations caused by cancer cells are reflected in the production burden of
altered proteins, and their presence results in the priming and activation of the host immune system.
In turn, they can potentially be identified as foreign antigens [33]. UC harbors the fourth highest rates
of mutations of all cancers and is known to be highly antigenic [34,35]. The understanding based on
these findings and principles provides the rationale for the clinical application of immunotherapy
in UC.
5.2. First-Line Immunotherapy for Cisplatin-Ineligible Patients
Cisplatin-based chemotherapy is the treatment of choice in the first-line setting for locally advanced
and metastatic UC. However, due to low tolerance and the short duration of response, an alternative
approach for the treatment of UC is imperative. Two clinical trials of the anti-PD-1/PD-L1 chemotherapy
agents (atezolizumab and pembrolizumab) for first-line treatment of cisplatin-ineligible patients with
metastatic UC showed these agents to be feasible and safe [36–38].
The anti-PD-1 antibody pembrolizumab was investigated in the KEYNOTE-052 trial for
cisplatin-ineligible patients with metastatic disease [37,38]. PD-L1 expression and ORR in the overall
cohort were the primary endpoints. The ORR and complete response (CR) rate were observed in 29%
and 7% of patients, respectively. Patients with a PD-L1 expression combined positive score (CPS)
of ≥10 showed a more prolonged median OS compared to the overall cohort (18.5 months vs. 11.5
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months). These results supported the fast track approval of pembrolizumab for cisplatin-ineligible
patients in the first-line setting [37,38].
Atezolizumab was approved following IMVigor210, a phase II trial involving 119 treatment-naïve
cisplatin-ineligible patients with metastatic UC. The majority of the cohort consisted of patients
ineligible for cisplatin due to renal insufficiency and low ECOG performance status; however,
a substantial proportion of patients were ineligible due to a history of hearing impairment and
peripheral neuropathy [36]. The primary endpoint was ORR and the CPS of PD-L1 expression.
Compared to the second-line setting with atezolizumab, a higher ORR was noted in the first-line
setting [36]. The U.S. Food and Drug Administration (FDA) approval was granted for atezolizumab in
the first-line setting for cisplatin-ineligible patients with locally advanced or metastatic UC (Table 2).
Table 2. Current U.S. Food and Drug Administration (FDA) approved immunotherapies for patients
with advanced or metastatic urothelial carcinoma.
Agent FDA Approval Type Trial Indication
Atezolizumab May 2016 Anti PD-L1 IMvigor 210[36]
First-line: PD-L1 positive (PD-L1 expression
≥5%) cisplatin-ineligible or platinum-ineligible
patients with advanced or metastatic UC
Second-line: advanced or metastatic UC
following platinum-containing
chemotherapy failure
Avelumab May 2017 Anti PD-L1 JAVELIN [39]
Second-line: advanced or metastatic UC
following failure of
platinum-based chemotherapy
Durvalumab May 2017 Anti PD-L1 Study 1108 [40]
Second-line: advanced or metastatic UC
following failure of
platinum-based chemotherapy
Nivolumab Feb 2017 Anti PD-1 CheckMate-275[41]
Second-line: advanced or metastatic UC
following failure of
platinum-based chemotherapy
Pembrolizumab May 2017 Anti PD-1 KEYNOTE-045[42]
First-line: PD-L1 positive (CPS ≥10)
cisplatin-ineligible patients with advanced or
metastatic UC or patients ineligible for any
platinum-based chemotherapy
Second-line: advanced or metastatic UC
following platinum-containing
chemotherapy failure
CPS, combined positive score; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1; UC,
urothelial carcinoma.
Two trials are investigating the feasibility of a first-line checkpoint inhibition and platinum-based
chemotherapy combination after FDA approvals were given for pembrolizumab and atezolizumab for
the first- and second-line treatment in cisplatin-ineligible patients.
The efficacy of first-line pembrolizumab with or without chemotherapy (GC or GemCarbo) versus
chemotherapy alone for the treatment of metastatic UC is being investigated in a randomized phase III
trial (KEYNOTE-361) (Table 3) [43]. IMvigor130 is an ongoing trial of a similar design to investigate the
efficacy of atezolizumab (Table 3) [44]. The outcomes of both trials will be stratified by PD-L1 status and
cisplatin-eligibility. Early reports have shown that patients with low PD-L1 status in the monotherapy
(pembrolizumab or atezolizumab) arms of both trials have inferior survival compared to those with
low PD-L1 status in the cisplatin- or carboplatin-based chemotherapy arms. Consequently, the FDA
issued a safety alert restricting the use of these immunotherapeutic agents to patients ineligible for
cisplatin, patients with low PD-L1 expression tumors, or for patients ineligible for platinum-containing
therapy regardless of PD-L1 expression.
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Table 3. Ongoing trials evaluating a combination of chemotherapy and immunotherapy for
urothelial carcinoma.
Combination Agents Clinical Phase Identifier Indication PrimaryEndpoints
Pembrolizumab +
chemotherapy III
NCT02853305
(KEYNOTE-361) [43]
First-line: cisplatin-eligible
and ineligible patients PFS and OS
Atezolizumab +
gemcitabine +
carboplatin/cisplatin
III NCT02807636(IMvigor 130) [44]
First-line: locally
advanced or metastatic UC
PFS, OS, safety, and
tolerability
Durvalumab +
gemcitabine +
carboplatin/cisplatin
III NCT03682068(NILE) [45]
First-line: locally
advanced or metastatic UC PFS and OS
OS: overall survival; PFS: progression-free survival; UC: urothelial carcinoma.
5.3. Second-Line Immunotherapy for Patients with Locally Advanced or Metastatic Urothelial Cancer
Following the failure of first-line chemotherapy, metastatic UC is a fatal disease with an OS of
6 to 7 months [46]. The application of immune checkpoint inhibitors to the patient population of
platinum-refractory UC has modernized the treatment with noteworthy toxicity profiles and durable
responses in patients with UC in the second-line setting. Since 2016, five new checkpoint inhibitors
targeting PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, and avelumab)
have gained FDA approval (Table 2) for the treatment of advanced or metastatic UC.
IMvigor210 was a phase II study to assess the activity of the PD-L1 antibody atezolizumab in
patients with advanced UC. Results were analyzed according to PD-L1 expression on tumor-infiltrating
immune cells (ICs) assessed by immunohistochemistry (Ventana SP142 assay) [47]. The PD-L1
tumor-infiltrating IC status was defined by the ratio of PD-L1 positive immune cells, consequently
dividing the tumors into three groups: IC0 (<1%), IC1 (≥1% to <5%) and IC2/3 (≥5%). In patients
with platinum-refractory metastatic UC, the IC2/3 subgroup showed higher ORR compared to the
counterpart [4]. The FDA approved atezolizumab in 2016 for patients with relapse as a second-line,
post-chemotherapy setting.
The recently completed IMvigor211 [48] was an open-label confirmatory phase III randomized
trial that compared atezolizumab to the investigator’s choice chemotherapy (taxanes or vinflunine)
for platinum-refractory metastatic UC. This study had a hierarchical statistical design to compare
differences in OS among the IC2/3 subgroup. However, no significant improvements in OS were shown
in the IC2/3 group. Despite failing to meet its primary endpoint, exploratory analysis in the intention
to treat population showed durable responses and survival benefits for atezolizumab.
Based on the results from a randomized phase III trial that included patients with
platinum-refractory UC (KEYNOTE-045), pembrolizumab was FDA-approved for locally advanced or
metastatic UC in the post-chemotherapy setting (Table 2) [42]. The KEYNOTE-045 trial compared OS
and progression-free survival (PFS) among the overall cohort and the PD-L1 positive subgroup (CPS
≥10%). CPS was defined as the ratio of the number of PD-L1 expressing cells to the total number of
tumor cells [49]. Notably, pembrolizumab prolonged OS regardless of PD-L1 status. In contrast to the
IMvigor211 trial in which the chemotherapy arm exhibited better survival outcomes in the PD-L1-high
subgroup, the PD-L1-high subgroups of KEYNOTE-045 failed to improve survival in either treatment
arm. The data monitoring committee of the study recommended early termination of the trial after it
met the primary endpoint for OS [42]. Long-term follow-up data showed that the survival benefit was
maintained at 24 months [50].
Nivolumab is a human monoclonal antibody that targets PD-1. The CheckMate 032, a
non-randomized phase I/II trial, investigated the feasibility of nivolumab alone for advanced UC
patients [51]. The primary endpoints were ORR and progression-free survival, with OS being a
secondary endpoint. Treatment with nivolumab provided durable clinical responses in patients with
platinum-refractory, locally advanced, or metastatic UC [51]. CheckMate 275 was a single-arm phase
II study of nivolumab in patients with platinum-refractory metastatic UC [41]. The study endpoint
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was ORR in the overall group and the subgroups of patients expressing PD-L1 levels ≥5% and ≥1%.
ORRs with a median follow-up of 7 months was 19.6% in the overall population, 28.4% in the PD-L1
≥5% subgroup, 23.8% in the PD-L1 ≥ 1% subgroup, and 16.1% in the PD-L1-negative subgroup. After
observing a significant improvement in OS among all PD-L1 subgroups and the need for an alternative
in the second-line setting, the FDA approved nivolumab in 2017 (Table 2).
Study 1108, a single-arm phase I/II study, investigated the efficacy of durvalumab (PD-L1 antibody)
in patients with metastatic UC who progressed after platinum-based chemotherapy [40,52]. The study
utilized the Ventana SP263 assay for PD-L1 expression, using a cutoff of 25% of PD-L1 positivity on
either the tumor cells or the ICs [53]. Responses were observed regardless of PD-L1 expression status.
Patients with PD-L1-high tumors achieved a response rate of 46% and a superior OS of 20 months,
compared to 8 months in patients with PD-L1-low tumors. Durvalumab was granted FDA approval in
2017 (Table 2).
JAVELIN was a multi-cohort phase Ib trial of avelumab, a human anti-PD-L1 IgG1 antibody,
involving patients with metastatic UC who were platinum-refractory or cisplatin-ineligible [39]. Results
were analyzed according to PD-L1 status in which the level of positive tumor cells was dichotomized at
5%. The ORR was 40% in the PD-L1-positive subgroup, while 9% was observed in the PD-L1-negative
subgroup. Avelumab was granted accelerated FDA approval in 2017 (Table 2).
6. Combination Therapy for Locally Advanced and Metastatic Urothelial Carcinoma
Despite promising results of the immune checkpoint inhibitor monotherapy, low long-term
durable ORR and high relapse rates warrant alternative approaches for the treatment of metastatic
UC. Evidence from studies advocating the immunosuppressive effects of chemotherapy has led
to the combination treatment of cytotoxic therapy, which may enhance the efficacy of checkpoint
inhibitors [54,55]. However, the results of a phase II, single-arm trial with a combination regimen of
GC and ipilimumab failed to achieve its primary endpoint of a one-year OS of >60% [56].
Ongoing trials are continuing to investigate the efficacy of a systemic chemotherapy and checkpoint
inhibitor combination in metastatic disease. KEYNOTE-361, a randomized, open-label, phase III
trial, compares the efficacies of pembrolizumab, pembrolizumab with or without chemotherapy, and
chemotherapy alone for advanced disease. Patients who are cisplatin-eligible will receive GC, and
those assigned to chemotherapy who are cisplatin-ineligible will receive GemCarbo. Primary endpoints
are OS and PFS, and secondary endpoints are ORR, safety, and tolerability (Table 3) [43]. IMvigor130,
a double-blind phase III trial, compares the efficacy and safety between first-line atezolizumab with
or without platinum-based chemotherapy and chemotherapy with placebo for locally advanced or
metastatic disease (Table 3) [44]. The NILE trial, a randomized phase III trial, investigates first-line
durvalumab with or without tremelimumab with standard chemotherapy followed by durvalumab,
versus standard of care alone as first-line chemotherapy for advanced or metastatic disease (Table 3) [45].
The primary endpoints are OS and PFS. Secondary endpoints are ORR, duration of response, and time
to second progression. Future application of these potential regimens will be determined following the
results of the aforementioned clinical trials.
Treatment regimens that combine the inhibitions of the PD-1/PD-L1 and CTLA-4 pathways have
the potential for synergistic immunotherapeutic activity. While PD-1 mediates the effector phase of
the immune response, the CTLA-4 blockade mediates the priming phase of the immune response.
Therefore, the blockage of both immune pathways may enhance anti-tumor activity. The phase I/II
CheckMate 032 trial compared the efficacy between either nivolumab or one of two combinations
of nivolumab plus ipilimumab in platinum-refractory patients (Table 4) [57]. The combination of
1-mg/kg of nivolumab and 3-mg/kg of ipilimumab provided a higher ORR and CR rate compared to the
combination of 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab. Of note, treatment with nivolumab
monotherapy resulted in an ORR of 24.4% and a CR rate of 6% [57]. Results from the long-term
follow-up of the CheckMate 032 trial reported a higher dosage of ipilimumab to be associated with
enhanced antitumor activity without significant toxicities (Table 4) [58]. The combination regimen
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of 1-mg/kg of nivolumab with 3-mg/kg of ipilimumab provided a higher ORR of 12% and a longer
duration of response. Compared to previous reports of PD-1 and PD-L1 monotherapy regimens, a
higher ORR and longer PFS and OS rates were achievable with a higher dosage of ipilimumab in the
PD-L1 unselected cohort [58]. Based on these results, the combination of a 1-mg/kg of nivolumab and
a 3-mg/kg of ipilimumab is being further investigated in the ongoing CheckMate 901 phase III trial, a
study of nivolumab with or without ipilimumab versus standard-of-care cisplatin- or carboplatin-based
chemotherapy for the management of metastatic UC in the first-line setting (Table 4) [59].
Table 4. Ongoing trials evaluating a combination of immunotherapies for urothelial carcinoma.
Combination
Agents Clinical Phase Identifier Indication
Primary
Endpoints
Ipilimumab +
nivolumab I/II
NCT01928394
(CheckMate 032)
[57,58]
Second-line:
platinum-refractory
advanced UC
ORR
Ipilimumab +
nivolumab III
NCT03036098
(CheckMate 901)
[59]
First-line:
cisplatin-eligible
and ineligible
patients
PFS and OS among
cisplatin-ineligible
patients
Durvalumab +
tremelimumab III
NCT02516241
(DANUBE) [60]
First-line:
cisplatin-eligible
and ineligible
patients
OS among
combination arm
and PD-L1-high
patients in the
monotherapy arm
ORR: objective response rate; OS: overall survival; PFS: progression-free survival; UC: urothelial carcinoma.
Therapy with durvalumab alone or in combination with tremelimumab is being investigated in a
randomized phase II trial (NCT02527434), in which their sequential use is being evaluated regarding
safety and efficacy in multiple malignancies. The durvalumab and tremelimumab combination
for patients with unresectable stage IV bladder cancer is being evaluated in the DANUBE study, a
randomized phase III trial (Table 4) [60]. The primary endpoint is PFS, and the outcomes will be
assessed according to PD-L1 status and cisplatin-eligibility.
7. Novel Therapeutic Agents for the Treatment of Urothelial Carcinoma
7.1. Anti-Angiogenic Therapies
Tumor proliferation is a coordinated result caused by simultaneous activation of the proangiogenic
pathways while the immune response is inhibited by the upregulation of immune checkpoint pathways.
Tumorigenesis is a process that involves both angiogenesis and immunosuppression in the tumor
microenvironment. In theory, simultaneously targeting both pathways may enhance the antitumor
capabilities of the immune system [61]. The first study to report data in UC combined a VEGFR-2
antibody, ramucirumab, with the PD-1 antibody pembrolizumab. In a phase I study (Table 5),
investigators reported that the combination was well tolerated and showed modest antitumor properties
for platinum-refractory metastatic UC [62,63]. A recent phase II study compared the efficacy between
docetaxel monotherapy and docetaxel plus ramucirumab or icrucumab in platinum-pretreated patients
with locally advanced or metastatic disease [64]. The primary endpoint was unmet; however, PFS was
significantly prolonged with the ramucirumab and docetaxel combination [64]. Consistent results
were obtained from the subsequent RANGE study, in which a longer PFS was observed with the
ramucirumab and docetaxel combination compared to docetaxel-alone (4.1 months vs. 2.8 months) [65].
However, OS outcomes were comparable between both arms [65].
Cancers 2020, 12, 192 10 of 22
Table 5. Ongoing trials evaluating anti-angiogenic therapies for urothelial carcinoma.
Combination
Agents Clinical Phase Identifier Indication
Primary
Endpoints
Ramicirumab +
pembrolizumab I NCT02443324 [62]
Second-line:
platinum-refractory
advanced UC
Safety
Cabozantinib +
nivolumab ±
ipilimumab
I NCT02496208 [66] Second-line Safety and toxicity
Axitinib +
avelumab II
NCT03472560
(JAVELIN Medley
VEGF) [67]
First-line:
cisplatin-ineligible
metastatic UC
ORR
ORR: objective response rate; UC: urothelial carcinoma; VEGF: vascular endothelial growth factor.
Bevacizumab, a vascular endothelial growth factor (VEGF)-A monoclonal antibody, has shown
promising results for metastatic disease. A phase II trial of GC and bevacizumab in the first-line setting
of metastatic disease resulted in an OS of 19.1 months and an ORR of 72% [68]. This regimen is being
investigated in a phase III trial that compares the efficacy of GC regimen with or without bevacizumab
(NCT00942331) [69].
Cabozantinib is a multi-kinase inhibitor that targets c-MET, RET, and VEGFR-2, and its combination
with checkpoint inhibitors is being investigated [70]. The efficacy of combining cabozantinib with
either nivolumab or ipilimumab/nivolumab was evaluated in a phase I trial (Table 5), which provided
an ORR of 36% across all genitourinary malignancies [66]. Moreover, additional clinical trials are
in progress for the evaluation of combining cabozantinib with atezolizumab (NCT03170960) and
pembrolizumab (NCT03534804) [71].
Axitinib, a selective inhibitor of VEGF receptors, is under evaluation for the combined treatment
with avelumab in the JAVELIN Medley VEGF trial, a phase II study involving cisplatin-ineligible
patients with non-small cell lung carcinoma and metastatic UC in the first-line setting (Table 4) [67].
Lastly, apatinib, a molecule inhibitor of VEGFR-2, is being evaluated for clinical efficacy in
combination with pembrolizumab for the treatment of patients with platinum-refractory metastatic
UC (NCT03407976) [72].
7.2. Gene-Targeted Therapies
Research from previous studies suggests that gene-targeted therapies may accentuate the
anti-tumor response of immunotherapy through upregulated immune-mediated killing and inhibition
of tumor-mediated immunosuppression [73]. While the majority of fibroblast growth factor receptor
(FGFR) mutations are more frequent in non-muscle invasive bladder cancer, alterations in FGFR3 have
been observed in particular subtypes of UC. A phase II study of erdafitinib showed an ORR rate of 42%
and a CR rate of 3%, with an 80% disease control rate in metastatic chemo-refractory patients with
FGFR alterations. Notably, an ORR of 70% was observed in patients treated with checkpoint inhibitors,
which is generally a population with a high unmet need for alternative treatment strategies due to poor
prognosis [74]. Erdafitinib was FDA-approved in 2019 for patients with FGFR2 and FGFR3-altered
advanced UC. At the same time, the first PCR-based diagnostic kit was FDA-approved to detect FGFR
alterations in patients with metastatic UC for selecting optimal candidates for erdafitinib administration.
Patients with tumors that have FGFR3 mutation or FGFR fusion are eligible for treatment with
AZD4547, an FGFR inhibitor, either as monotherapy or in combination with duvalumab [75]. FORT-2
(NCT03473756; Table 6) is a phase I/II trial of the novel FGFR inhibitor, rogaratinib in combination with
atezolizumab [76], and the FIERCE-22 (NCT03123055; Table 6) is a phase I/II trial of pembrolizumab in
combination with vofatamab (B-701), a FGFR3 inhibitor [77].
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Table 6. Ongoing trials evaluating gene-targeted therapies for urothelial carcinoma.
Combination
Agents Mechanism Clinical Phase Identifier Indication
Primary
Endpoints
Rogaratinib +
atezolizumab
FGFR target
therapy I/II
NCT03473756
(FORT-2) [76]
First-line:
cisplatin-ineligible
UC
Toxicity and
PFS
Vofatamab +
pembrolizumab
FGFR target
therapy I/II
NCT03123055
(FIERCE-22)
[77]
Second-line Safety, toxicity,and ORR
FGFR: fibroblast growth factor receptor; ORR: objective response rate; PFS: progression-free survival; UC:
urothelial carcinoma.
7.3. Antibody-Drug Conjugate Therapies
Antibody-drug conjugates (ADC) consist of a protease cleavable linker bound to a cytotoxic agent
and a monoclonal antibody that is specific to a highly expressed cancer cell target. The cytotoxic
agent is discharged in tumor cells after the lysosomal degradation and internalization of the ADC.
ASG-15ME is an ADC that targets SLITRK6, a type I transmembrane neuronal receptor, and has shown
positive results in trials regarding UC. SLITRK6 expression is present in 90% of all UCs [78]. In a phase
I trial of 51 pretreated patients with metastatic UC who were administered ASG-15ME, results showed
an ORR of 37.5% along with 17 (33.3%) partial responses and one (2.0%) CR [79].
Enfortumab vedotin is an ADC comprised of an antibody to nectin-4 bound to a cytotoxic
microtubule-disrupting agent, which has shown efficacy in patients with metastatic, platinum-refractory
UC. Enfortumab vedotin targets nectin-4, a cell adhesion molecule highly expressed in multiple
malignancies, including UC [80]. Enfortumab vedotin was FDA-approved for patients with locally
advanced or metastatic disease who have previously received immune checkpoint therapy based on
a phase I trial evaluating enfortumab vedotin as a monotherapy. Updated data from a phase I trial
evaluating the efficacy of enfortumab vedotin as a second-line treatment in patients with metastatic
disease demonstrated an ORR of 40% [81]. Given these impressive outcomes as a monotherapy regimen,
a phase I trial (NCT03299545, EV-103) has been initiated to investigate the efficacy of enfortumab
vedotin in combination with either atezolizumab or pembrolizumab in both first-line cisplatin-ineligible
and platinum-refractory settings [82].
7.4. Vaccines
Vaccines may also play a role in immunotherapeutic strategies for UC. Oncoproteins, including
human epidermal growth factor receptor 2 (HER2), cancer/testis antigens (CTAs), and tumor-associated
antigens, namely, carcinoembryonic antigen (CEA), Mucin-1 (MUC-1), and human chorionic
gonadotropin-β (hCG-β), are promising targets. A phase II study (NCT01353222) investigated
the therapeutic feasibility of DN24-02 in HER2+ UC patients who are at high risk of relapse following
surgery (Table 7). DN24-02 is an autologous immunotherapeutic vaccine that stimulates an immune
response against HER2/neu. The vaccine consists of autologous peripheral blood mononuclear cells
and APCs that are activated ex vivo with BA7072, a recombinant fusion protein. Results showed that
in patients who completed the three infusion cycles, the vaccine increased HER2 antibody responses,
serum cytokines (IL-2, IFN-γ, and TNF-α), in vitro IL-2 and IFN-γ accumulation, and antigen-specific T
cell responses compared to patients who received standard-of-care surveillance. In subgroup analysis,
patients with low tumor burden exhibited more favorable hazard ratios for OS; however, DN24-02
failed to increase OS or recurrence-free survival in the overall group. This study was terminated early
due to administrative reasons [83].
Cancers 2020, 12, 192 12 of 22
Table 7. Trials evaluating vaccine therapies for urothelial carcinoma.
Agent ClinicalPhase Identifier Indication
Primary
Endpoints
DN24-02 II NCT01353222 [83] High-risk HER2+ UC with or withoutprior neoadjuvant chemotherapy OS
DC205-NY-ESO-1 I NCT01522820 [84] Patients with cancer-testis antigen(NY-ESO-1) expressing solid tumors Safety and toxicity
MAGE-A3 ASCI I NCT01498172 [85] Non-muscle invasive bladder cancer Adverse events
PANVAC II NCT02015104 [86] BCG-relapsing, high-grade,non-muscle invasive bladder cancer DFS
CDX-1307 I NCT00709462 [87] Incurable bladder cancer Safety andtolerability
BCG: Bacillus Calmette-Guerin; DFS: disease-free survival; OS: overall survival; UC: urothelial carcinoma.
CTAs are tumor-associated antigens that elicit a robust immune response and have shown variable
expressions in various malignancies. New York esophageal squamous cell cancer 1 (NY-ESO-1) and
melanoma-associated antigen-A3 (MAGE A3) are CTAs that are associated with UC. Sharma et al.
investigated the feasibility of a recombinant NY-ESO-1 protein vaccine with BCG and GM-CSF as
immunological adjuvants in post-cystectomy patients [88]. NY-ESO-1-specific antibody responses were
observed, inferring the efficacy of the recombinant NY-ESO-1 protein vaccine to elicit predominant
antibody and CD4+ T cell responses. An ongoing phase I clinical trial (NCT01522820) is investigating
the safety of NY-ESO-1 vaccine (DEC-205/NY-ESO-1 fusion protein CDX-1401) with or without sirolimus
administration in cancer patients with NY-ESO-1 expression (Table 7) [84]. A recently completed
non-randomized phase I exploratory study investigated the efficacy of combined intravesical BCG
instillation with recombinant MAGE-A3 and immunostimulant AS15 in patients with non-muscle
invasive bladder cancer (Table 7) [85]. In half of the patients in that study, intravesical vaccine-specific
T cells were increased with a tolerable safety profile. The results inferred that combinations of T-cell
vaccines with local immunotherapy may increase total and vaccine-specific T cells in the bladder.
PANVAC is a pox viral cancer vaccine that expresses transgenes for CEA, MUC-1, and T cell
costimulatory molecules (B7-1, intracellular adhesion molecule 1, and leukocyte function-associated
antigen 3) to boost the anti-tumor T cell immune response. The rationale for this treatment modality
is based on studies that have shown increased expression of MUC-1 and CEA in patients with
bladder cancer [89,90]. A phase II trial assessed the efficacy of PANVAC with BCG compared to
BCG monotherapy in patients with BCG-relapsing non-muscle invasive bladder cancer (Table 7) [86].
Higher rates of tumor-associated antigen response regarding CEA and MUC1 were observed with
PANVAC and BCG combination compared to BCG alone.
CDX-1307 is a vaccine that consists of a mannose receptor-specific human monoclonal antibody
fused to hCG-β, a tumor antigen frequently expressed in epithelial cancers, including UC [87]. Cytotoxic
T-lymphocytes are mediators of antitumor immunity; therefore, a vaccine that induces both cellular
and humoral responses to hCG-β is feasible. CDX-1307 presents hCG-β protein to APCs and promotes
hCG-β-specific cellular and humoral immune responses. In a phase I trial involving patients with
advanced epithelial cancers, the combination of CDX-1307 and immune-stimulating adjuvants induced
anti-hCG-β humoral and T cell responses with an acceptable safety profile (Table 7) [87]. Based on
these results, a phase II trial (N-ABLE) was initiated to assess the efficacy of CDX-1307 vaccine regimen
in patients with hCG-β positive, non-metastatic, muscle-invasive bladder cancer [91]. However, the
trial was terminated early due to slow enrollment.
7.5. Adoptive T Cell Immunotherapy
Adoptive T cell therapy is a highly custom-tailored cancer therapy that consists of the harvest,
proliferation, and modification of human T cells ex vivo, and reinfusion. The promise of adoptive T
cell immunotherapy utilizing tumor-infiltrating lymphocytes was based on a study in which more
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than 50% of patients with advanced melanoma showed a response to treatment [92]. In a clinical study
involving patients with metastatic bladder cancer, tumor-reactive lymphocytes were extracted from
tumor-draining lymph nodes, followed by in vitro expansion of T lymphocytes against autologous
tumor extract, and subsequent reinfusion. In two out of nine patients, durable objective responses
were observed without significant adverse effects [93].
In an attempt to broaden the arsenal of adoptive T cell therapy, genetic modification with chimeric
antigen receptors (CARs) is in development. CARs consist of antibody-binding domains that are
fused to T cell signal domains, allowing a higher affinity binding of target antigens regardless of
human leukocyte antigen subtypes [94]. Clinical application of CAR T cells has shown promising
antitumor activity in B cell malignancies [95,96]. However, low efficacy and high occurrence of toxicity,
which were observed in several trials involving solid tumors, still remain as limitations of CAR T cell
immunotherapy [97,98]. Further studies and advancements in genetic engineering to modify CARs
and combination strategies with other immunotherapeutics are warranted to overcome the current
limitations of adoptive T cell immunotherapy.
8. Biomarkers for Predicting Treatment Response
Research and clinical trials are investigating biomarkers that provide information on future
responses to cancer immunotherapy [99]. Since patients with advanced UC have low durable response
rates, the identification of the patient population likely to benefit from a certain therapy is imperative.
Treatment response is associated with multiple factors, including both tumor and immunological
factors; therefore, the development of reliable biomarkers is challenging. However, reliable biomarkers
may reduce overtreatment in patients without survival benefit and avoid adverse events resulting
from treatment.
During the developmental stages of the anti-PD-1/PD-L1 inhibitor, PD-L1 expression on tumor
cells or ICs has gained attention as a potential biomarker for checkpoint inhibitors. The Ventana assay
used to assess PD-L1 expression in ICs in the cohort 2 of the IMvigor210 trial defined positive PD-L1 as
an expression in ≥5% of infiltrating ICs [36,100]. Although the ORR was higher in the PD-L1-positive
patients, a 9% response rate was still noted in PD-L1-negative patients. Overall, PD-L1 positivity
appears to have a prognostic effect, as shown by the higher OS in the PD-L1-positive subgroup in
comparison with the PD-L1-negative subgroup. Nevertheless, in the cisplatin-ineligible cohort 1 of
the IMvigor210 trial, PD-L1-negative patients exhibited superior OS in comparison to PD-L1-positive
patients [100].
In the KEYNOTE-052 trial, the Dako antibody assay was utilized to define PD-L1 positivity, in
which a score of ≥10% was considered positive for PD-L1. Patients with a CPS of ≥10% demonstrated
a higher response to pembrolizumab compared to patients with a CPS of <10% [38]. On the other
hand, CPS was not associated with ORR in the larger KEYNOTE-045 trial [42]. The different assays
used in these trials and the different definitions for PD-L1 positivity are hurdles to defining the exact
prognostic significance of PD-L1 expression. Further studies are warranted to institute a uniform
method for evaluating PD-L1 expression to predict durable response.
In addition to PD-L1, other biomarkers such as tumor mutation burden (TMB), mismatch repair
(MMR) mechanism, and DNA damage response (DDR) and repair pathways are under investigation
and have shown promise as potential biomarkers reflecting the response to checkpoint inhibitors in
several cancers including UC [101–105]. TMB is the total number of somatic coding mutations found
in cancer cells, which represents the deficiency in the mismatch repair mechanism, tumor-infiltrating
lymphocytes, neoantigen burden, or immuno-genes signatures. Studies have shown the association
of TMB with the tumor response after administration of checkpoint inhibitors in UC and other
malignancies. Furthermore, the role of TMB as a biomarker was studied in the post hoc analysis of
the IMvigor210 trial, which revealed that patients with a high TMB and luminal cluster II molecular
subtypes showed favorable outcomes [36,104]. While further validation is needed, malignancies with
MMR defects showed to be responsive to pembrolizumab regardless of the primary source of origin.
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Based on these results, pembrolizumab was FDA-approved for all malignancies with this specific
alteration [102].
Variations in DNA repair pathways are feasible biomarkers for cisplatin sensitivity since such
alterations exacerbate the intrinsic cellular DNA repair mechanism. A study has shown that low
excision repair cross-complementing 1 (ERCC1) mRNA expressing tumors were associated with
prolonged survival [106]. These findings were confirmed in a subsequent meta-analysis of advanced
UC patients who underwent platinum-based chemotherapy [105]. A recent study demonstrated
that patients with metastatic disease with somatic mutations in DDR proteins to exhibit significantly
improved clinical outcomes [107]. Patients with one or more DDR alterations had improved PFS and
OS with platinum-based chemotherapy compared to those with no detectable DDR alterations.
9. Pseudoprogression and Hyperprogression during Immunotherapy for Urothelial Cancer
Immunotherapy has gained a pivotal role in cancer therapy and has changed the paradigm
of advanced UC treatment. However, this represents a challenge to uro-oncologists due to the
unique patient responses and side effects resulting from a mechanism of action different from that of
conventional chemotherapy. Various clinical trials based on advanced UC have shown that a minority
of the patients experience atypical responses to checkpoint inhibitors, namely hyperprogression
and pseudoprogression.
Hyperprogression is the rapid paradoxical disease progression after treatment with
immunotherapeutic agents, which was first described in patients with melanoma. Champiat et
al. reported a prevalence of 6% in patients with multiple solid tumors or lymphoma treated with
immunotherapies [108]. The pathogenesis underlying this pattern of clinical progression is still
undefined due to the limited number of events reported, the absence of a validated definition, and the
apparent absence of a definable biological mechanism [109]. Therefore, results from ongoing clinical
trials are needed to confirm the hypothetical mechanisms.
Pseudoprogression is another phenomenon that immunotherapy patients may encounter. The
tumor initially increases in size but gradually stabilizes or responds to ongoing treatment. The
actual prevalence of such clinical entity in UC is unclear; however, according to retrospective
reviews performed by Soria et al., the prevalence of pseudoprogression has an approximate range
from 1.5% to 17% [110]. The pathophysiology underlying this phenomenon is considered to be a
consequence of the infiltration of ICs within the neoplasm and subsequent temporary increase in
volume. A revised radiological criterion to evaluate response in patients treated with immunotherapy
has been developed, specifically the immune-response evaluation criteria in solid tumors (iRECIST),
which can be utilized to categorize pseudoprogression and other peculiar radiological patterns [111].
The evidence available on this phenomenon is mostly from studies involving other solid malignancies.
Therefore, the accumulation of data from UC cohorts is warranted to better define and manage this
clinical manifestation associated with immunotherapy.
10. Conclusions
Development and research of the PD-1/L1 axis blockade have changed the contemporary treatment
paradigm for patients with metastatic UC. The recent approvals of pembrolizumab and atezolizumab
for platinum/cisplatin-ineligible patients and checkpoint inhibitors in the second-line setting have
redefined the treatment landscape for locally advanced and metastatic UCs. Ongoing clinical trials plan
to assess the efficacies of PD-1/L1 antibodies in the first-line setting and to provide further insights into
the utilization of PD-L1 expression as a predictive biomarker. Combination immunotherapy regimens,
targeted therapies, and antibody-drug conjugates are showing considerable potential as treatment
options for UC. The shift in the treatment paradigm, along with the abundance of novel investigational
agents, calls for the need to investigate combinations and sequencing of agents in future clinical trials.
Cancers 2020, 12, 192 15 of 22
Author Contributions: Conceptualization, T.J.K. and K.C.K.; writing-original draft preparation, T.J.K;
writing-review and editing, K.S.C. and K.C.K.; supervision and project administration, K.C.K. All authors
have read and agree to the published version of the manuscript.
Funding: This study was supported by the Young Researcher Program Grant of the National Research Foundation
of Korea (NRF-2017R1C1B5017516).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Siegel, R.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [CrossRef]
[PubMed]
2. Chang, S.S.; Bochner, B.H.; Chou, R.; Dreicer, R.; Kamat, A.M.; Lerner, S.P.; Lotan, Y.; Meeks, J.J.; Michalski, J.M.;
Morgan, T.M.; et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO
Guideline. J. Urol. 2017, 198, 552–559. [CrossRef] [PubMed]
3. Spiess, P.E.; Agarwal, N.; Bangs, R.; Boorjian, S.A.; Buyyounouski, M.K.; Clark, P.E.; Downs, T.M.;
Efstathiou, J.A.; Flaig, T.W.; Friedlander, T.; et al. Bladder cancer, version 5. 2017, NCCN Clinical
Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017, 15, 1240–1267. [CrossRef] [PubMed]
4. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.;
O’Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; et al. Atezolizumab in patients with locally advanced
and metastatic urothelial carcinoma who have progressed following treatment with platinum-based
chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016, 387, 1909–1920. [CrossRef]
5. Lopez-Beltran, A.; Henriques, V.; Montironi, R.; Cimadamore, A.; Raspollini, M.R.; Cheng, L. Variants and
new entities of bladder cancer. Histopathology 2019, 74, 77–96. [CrossRef] [PubMed]
6. Moch, H.; Humphrey, P.A.; Ulbright, T.M.; Reuter, V. WHO Classification of Tumours of the Urinary System and
Male Genital Organs; International Agency for Research on Cancer: Lyon, France, 2016.
7. Kim, S.P.; Frank, I.; Cheville, J.C.; Thompson, R.H.; Weight, C.J.; Thapa, P.; Boorjian, S.A. The impact of
squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J. Urol.
2012, 188, 405–409. [CrossRef] [PubMed]
8. Scosyrev, E.; Ely, B.W.; Messing, E.M.; Speights, V.O.; Grossman, H.B.; Wood, D.P.; de Vere White, R.W.;
Vogelzang, N.J.; Trump, D.L.; Natale, R.B.; et al. Do mixed histological features affect survival benefit from
neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?
A secondary analysis of Southwest Oncology Group- Directed Intergroup Study (S8710). BJU Int. 2011, 108,
693–699. [CrossRef]
9. Tamas, E.F.; Nielsen, M.E.; Schoenberg, M.P.; Epstein, J.I. Lymphoepithelioma-like carcinoma of the urinary
tract: A clinicopathological study of 30 pure and mixed cases. Mod. Pathol. 2007, 20, 828–834. [CrossRef]
10. Lopez-Beltran, A.; Paner, G.; Blanca, A.; Montironi, R.; Tsuzuki, T.; Nagashima, Y.; Chuang, S.S.; Win, K.T.;
Madruga, L.; Raspollini, M.R.; et al. Lymphoepithelioma-like carcinoma of the upper urinary tract.
Virchows Arch. 2017, 470, 703–709. [CrossRef]
11. Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A.D.; Hinoue, T.; Laird, P.W.;
Hoadley, K.A.; Akbani, R.; et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder
Cancer. Cell 2017, 171, 540–556. [CrossRef]
12. Roupret, M.; Babjuk, M.; Comperat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Böhle, A.;
Van Rhijn, B.W.; Kaasinen, E.; et al. European Association of Urology guidelines on upper urinary tract
urothelial cell carcinoma: 2015 update. Eur. Urol. 2015, 68, 868–879. [CrossRef] [PubMed]
13. Galsky, M.D.; Hahn, N.M.; Rosenberg, J.; Sonpavde, G.; Hutson, T.; Oh, W.K.; Dreicer, R.; Vogelzang, N.;
Sternberg, C.N.; Bajorin, D.F.; et al. Treatment of patients with metastatic urothelial cancer “unfit” for
cisplatin-based chemotherapy. J. Clin. Oncol. 2011, 29, 2432–2438. [CrossRef]
14. Kaufman, D.; Raghavan, D.; Carducci, M.; Levine, E.G.; Murphy, B.; Aisner, J.; Kuzel, T.; Nicol, S.; Oh, W.;
Stadler, W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin.
Oncol. 2000, 18, 1921–1927. [CrossRef] [PubMed]
Cancers 2020, 12, 192 16 of 22
15. von der Maase, H.; Hansen, S.W.; Roberts, J.T.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Bodrogi, I.; Albers, P.;
Knuth, A.; Lippert, C.M.; et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and
cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter,
phase III study. J. Clin. Oncol. 2000, 18, 3068–3077. [CrossRef] [PubMed]
16. McCaffrey, J.A.; Hilton, S.; Mazumdar, M.; Sadan, S.; Kelly, W.K.; Scher, H.I.; Bajorin, D.F. Phase II trial
of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 1997, 15,
1853–1857. [CrossRef] [PubMed]
17. Sweeney, C.J.; Roth, B.J.; Kabbinavar, F.F.; Vaughn, D.J.; Arning, M.; Curiel, R.E.; Obasaju, C.K.; Wang, Y.;
Nicol, S.J.; Kaufman, D.S. Phase II study of pemetrexed for second-line treatment of transitional cell cancer
of the urothelium. J. Clin. Oncol. 2006, 24, 3451–3457. [CrossRef]
18. Sternberg, C.N.; Yagoda, A.; Scher, H.I.; Watson, R.C.; Geller, N.; Herr, H.W.; Morse, M.J.; Sogani, P.C.;
Vaughan, E.D.; Bander, N.; et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced
transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989, 64,
2448–2458. [CrossRef]
19. Loehrer, P.J., Sr.; Einhorn, L.H.; Elson, P.J.; Crawford, E.D.; Kuebler, P.; Tannock, I.; Raghavan, D.;
Stuart-Harris, R.; Sarosdy, M.F.; Lowe, B.A.; et al. A randomized comparison of cisplatin alone or
in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial
carcinoma: A cooperative group study. J. Clin. Oncol. 1992, 10, 1066–1073. [CrossRef]
20. von der Maase, H.; Sengelov, L.; Roberts, J.T.; Ricci, S.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Zimmermann, A.;
Arning, M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with
methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23,
4602–4608. [CrossRef]
21. Bellmunt, J.; von der Maase, H.; Mead, G.M.; Skoneczna, I.; De Santis, M.; Daugaard, G.;
Boehle, A.; Chevreau, C.; Paz-Ares, L.; Laufman, L.R.; et al. Randomized phase III study comparing
paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic
urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 2012, 30,
1107–1113. [CrossRef]
22. Dash, A.; Galsky, M.D.; Vickers, A.J.; Serio, A.M.; Koppie, T.M.; Dalbagni, G.; Bochner, B.H. Impact of renal
impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of
the bladder. Cancer 2006, 107, 506–513. [CrossRef] [PubMed]
23. De Santis, M.; Bellmunt, J.; Mead, G.; Kerst, J.M.; Leahy, M.; Maroto, P.; Gil, T.; Marreaud, S.; Daugaard, G.;
Skoneczna, I.; et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/
carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based
chemotherapy: EORTC study 30986. J. Clin. Oncol. 2012, 30, 191–199. [CrossRef] [PubMed]
24. Hainsworth, J.D.; Meluch, A.A.; Litchy, S.; Schnell, F.M.; Bearden, J.D.; Yost, K.; Greco, F.A. Paclitaxel,
carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the
urothelium. Cancer 2005, 103, 2298–2303. [CrossRef] [PubMed]
25. Hurwitz, M.E.; Sokhn, J.; Petrylak, D.P. Cancer immunotherapy: New applications in urologic oncology.
Curr. Opin. Urol. 2016, 26, 535–542. [CrossRef] [PubMed]
26. Donin, N.M.; Lenis, A.T.; Holden, S.; Drakaki, A.; Pantuck, A.; Belldegrun, A.; Chamie, K. Immunotherapy
for the treatment of urothelial carcinoma. J. Urol. 2017, 197, 14–22. [CrossRef] [PubMed]
27. Anderson, A.C.; Anderson, D.E.; Bregoli, L.; Hastings, W.D.; Kassam, N.; Lei, C.; Chandwaskar, R.; Karman, J.;
Su, E.W.; Hirashima, M.; et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed
on innate immune cells. Science 2007, 318, 1141–1143. [CrossRef]
28. Schepisi, G.; Brighi, N.; Cursano, M.C.; Gurioli, G.; Ravaglia, G.; Altavilla, A.; Burgio, S.L.; Testoni, S.;
Menna, C.; Farolfi, A.; et al. Inflammatory biomarkers as predictors of response to immunotherapy in
urological tumors. J. Oncol. 2019, 11, e12. [CrossRef]
29. Sica, G.L.; Choi, I.H.; Zhu, G.; Tamada, K.; Wang, S.D.; Tamura, H.; Chapoval, A.I.; Flies, D.B.; Bajorath, J.;
Chen, L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18, 849–861.
[CrossRef]
30. Loos, M.; Hedderich, D.M.; Friess, H.; Kleeff, J. B7-H3 and its role in antitumor immunity. Clin. Dev. Immunol.
2010, 2010. [CrossRef]
Cancers 2020, 12, 192 17 of 22
31. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.;
Laheru, D.; et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372,
2509–2520. [CrossRef]
32. Kelderman, S.; Schumacher, T.N.; Kvistborg, P. Mismatch repair-deficient cancers are targets for anti-PD-1
therapy. Cancer Cell 2015, 28, 11–13. [CrossRef] [PubMed]
33. Singh, P.; Black, P. Emerging role of checkpoint inhibition in localized bladder cancer. In Urologic Oncology:
Seminars and Original Investigations; Elsevier: Amsterdam, The Netherlands, 2016; Volume 34, pp. 548–555.
34. Lawrence, M.S.; Stojanov, P.; Polak, P.; Kryukov, G.V.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.; Stewart, C.;
Mermel, C.H.; Roberts, S.A.; et al. Mutational heterogeneity in cancer and the search for new cancer-associated
genes. Nature 2013, 499, 214–218. [CrossRef]
35. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.;
Borg, A.; Børresen-Dale, A.L.; et al. Signatures of mutational processes in human cancer. Nature 2013, 500,
415–421. [CrossRef] [PubMed]
36. Balar, A.V.; Galsky, M.D.; Rosenberg, J.E.; Powles, T.; Petrylak, D.P.; Bellmunt, J.; Loriot, Y.; Necchi, A.;
Hoffman-Censits, J.; Perez-Gracia, J.L.; et al. Atezolizumab as first-line treatment in cisplatin ineligible
patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet 2017, 389, 67–76. [CrossRef]
37. O’Donnel, P.; Grivas, P.; Balar, A.V.; Bellmunt, J.; Vuky, J.; Powles, T.; Plimack, E.R.; Hahn, N.M.; De Wit, R.;
Pang, L.; et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab
(pembro) in cisplatin-ineligible advanced urothelial cancer (UC). In Proceedings of the 2017 ASCO Annual
Meeting Genitourinary (Nonprostate) Cancer Oral Abstract Session, Chicago, IL, USA, 2–6 June 2017.
38. Balar, A.V.; Castellano, D.; O’Donnell, P.H.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E.R.; Hahn, N.M.;
de Wit, R.; Pang, L.; et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced
and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study.
Lancet Oncol. 2017, 18, 1483–1492. [CrossRef]
39. Patel, M.R.; Ellerton, J.; Infante, J.R.; Agrawal, M.; Gordon, M.; Aljumaily, R.; Britten, C.D.; Dirix, L.; Lee, K.W.;
Taylor, M.; et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor):
Pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018, 19, 51–64.
[CrossRef]
40. Powles, T.; O’Donnell, P.H.; Massard, C.; Arkenau, H.T.; Friedlander, T.W.; Hoimes, C.J.; Lee, J.L.; Ong, M.;
Sridhar, S.S.; Vogelzang, N.J.; et al. Efficacy and safety of durvalumab in locally advanced or metastatic
urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol. 2017, 3, e172411.
[CrossRef]
41. Sharma, P.; Retz, M.; Siefker-Radtke, A.; Baron, A.; Necchi, A.; Bedke, J.; Plimack, E.R.; Vaena, D.; Grimm, M.O.;
Bracarda, S.; et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275):
A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017, 18, 312–322. [CrossRef]
42. Bellmunt, J.; de Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.;
Petrylak, D.P.; Choueiri, T.K.; et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma.
N. Engl. J. Med. 2017, 376, 1015–1026. [CrossRef]
43. Powles, T.; Gschwend, J.E.; Loriot, Y.; Bellmunt, J.; Geczi, L.; Vulsteke, C.; Abdelsalam, M.; Gafanov, R.;
Bae, W.K.; Revesz, J.; et al. Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without
chemotherapy versus chemotherapy alone in advanced urothelial cancer. J. Clin. Oncol. 2017, 35, e15.
[CrossRef]
44. Galsky, M.D.; Grande, E.; Davis, I.D.; Santis, M.D.; Arija, J.A.A.; Kikuchi, E.; Mecke, A.; Thastrom, A.C.;
Bamias, A. IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as
monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally
advanced or metastatic urothelial carcinoma (mUC). J. Clin. Oncol. 2018, 36, e15. [CrossRef]
45. Galsky, M.D.; Necchi, A.; Sridhar, S.S.; Ogawa, O.; Angra, N.; Hois, S.; He, P.; Ghiorghiu, D.C.; Bellmunt, J. A
phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination
with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC
chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic
urothelial cancer (UC). J. Clin. Oncol. 2019, 37, e15.
Cancers 2020, 12, 192 18 of 22
46. Bellmunt, J.; Theodore, C.; Demkov, T.; Komyakov, B.; Sengelov, L.; Daugaard, G.; Caty, A.; Carles, J.;
Jagiello-Gruszfeld, A.; Karyakin, O.; et al. Phase III trial of vinflunine plus best supportive care compared
with best supportive care alone after a platinum containing regimen in patients with advanced transitional
cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009, 27, 4454–4461. [CrossRef] [PubMed]
47. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.;
Powderly, J.D.; Gettinger, S.N.; et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A
in cancer patients. Nature 2014, 515, 563–567. [CrossRef] [PubMed]
48. Powles, T.; Duran, I.; van der Heijden, M.S.; Loriot, Y.; Vogelzang, N.J.; De Giorgi, U.; Oudard, S.; Retz, M.M.;
Castellano, D.; Bamias, A.; et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally
advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised
controlled trial. Lancet 2018, 391, 748–757. [CrossRef]
49. Balar, A.V.; Bellmunt, J.; O’Donnell, P.H.; Castellano, D.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E.R.;
Hahn, N.M.; de Wit, R.; et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or
metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Ann. Oncol. 2016, 27.
[CrossRef]
50. Bellmunt, J.; De Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.;
Choueiri, T.K.; et al. Two-year follow up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro)
vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). J.
Clin. Oncol. 2018, 36, e410. [CrossRef]
51. Sharma, P.; Callahan, M.K.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R.N.; Ott, P.A.; de Braud, F.;
Morse, M.; et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A
multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016, 17, 1590–1598. [CrossRef]
52. Massard, C.; Gordon, M.S.; Sharma, S.; Rafii, S.; Wainberg, Z.A.; Luke, J.; Curiel, T.J.; Colon-Otero, G.;
Hamid, O.; Sanborn, R.E.; et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell
death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin.
Oncol. 2016, 34, 3119–3125. [CrossRef]
53. Marlon Rebelatto, A.M.; Sabalos, C.; Walker, J.; Midha, A.; Steele, K.; Robbins, P.B.; Li, X.; Shi, L.;
Blake-Haskins, J.A.; Ibrahim, R.A.; et al. Development of a PD-L1 companion diagnostic assay for treatment
with MEDI4736 in NSCLC and SCCHN patients. J. Clin. Oncol. 2015, 33, e8033. [CrossRef]
54. Chang, C.H.; Qiu, J.; O’Sullivan, D.; Buck, M.D.; Noguchi, T.; Curtis, J.D.; Chen, Q.; Gindin, M.; Gubin, M.M.;
van der Windt, G.J.; et al. Metabolic competition in the tumor microenvironment is a driver of cancer
progression. Cell 2015, 162, 1229–1241. [CrossRef] [PubMed]
55. Hato, S.V.; Khong, A.; de Vries, I.J.; Lesterhuis, W.J. Molecular pathways: The immunogenic effects of
platinum-based chemotherapeutics. Clin. Cancer Res. 2014, 20, 2831–2837. [CrossRef] [PubMed]
56. Galsky, M.D.; Wang, H.; Hahn, N.M.; Twardowski, P.; Pal, S.K.; Albany, C.; Fleming, M.T.; Starodub, A.;
Hauke, R.J.; Yu, M.; et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic
urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur. Urol. 2018, 73,
751–759. [CrossRef] [PubMed]
57. Sharma, P.; Callahan, M.K.; Calvo, A. Efficacy and safety of nivolumab plus ipilimumab in previously treated
metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study. In Proceedings of the
2016 SITC Annual Meeting, National Harbor, Hyattsville, MD, USA, 9–13 November 2016.
58. Rosenberg, J.; Sharma, P.; De Braud, F.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P.A.;
Lopez-Martin, J.A.; Brossart, P.; et al. Nivolumab(N) alone or in combination with ipilimumab (I) in
patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1
mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. Ann. Oncol. 2018, 29, e32. [CrossRef]
59. Galsky, M.D.; Powles, T.; Li, S.; Hennicken, D.; Sonpavde, G. A phase 3, open-label, randomized study
of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously
untreated unresectable or metastatic urothelial carcinoma (mUC.; CheckMate 901). J. Clin. Oncol. 2018, 36,
TPS4588. [CrossRef]
60. Powles, T.; Galsky, M.D.; Castellano, D.; Van Der Heijden, M.S.; Petrylak, D.P.; Armstrong, J.; Belli, R.;
Ferro, S.; Ben., Y.; Bellmunt, J. A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus
standard of care (SoC) chemotherapy(CT) in patients (pts) with unresectable stage IV urothelial bladder
cancer (UBC): DANUBE. J. Clin. Oncol. 2016, 34, TPS4574. [CrossRef]
Cancers 2020, 12, 192 19 of 22
61. Motz, G.T.; Coukos, G. The parallel lives of angiogenesis and immunosuppression: Cancer and other tales.
Nat. Rev. Immunol. 2011, 11, 702–711. [CrossRef]
62. Petrylak, D.P.; Arkenau, H.-T.; Perez-Gracia, J.L.; Krebs, M.; Santana- Davila, R.; Yang, J.; Rege, J.; Mi, G.;
Ferry, D.; Herbst, R.S. A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim
safety and clinical activity in patients with urothelial carcinoma. J. Clin. Oncol. 2017, 35, e349. [CrossRef]
63. Herbst, R.S.; Chau, I.; Petrylak, D.P.; Arkenau, H.-T.; Bendell, J.C.; Santana-Davila, R.; Calvo, E.; Penel, N.;
Martin-Liberal, J.; Soriano, A.O.; et al. Activity of ramucirumab (R) with pembrolizumab(P) by PD-L1
expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. J. Clin. Oncol. 2018, 36, e3059.
[CrossRef]
64. Petrylak, D.P.; Tagawa, S.T.; Kohli, M.; Eisen, A.; Canil, C.; Sridhar, S.S.; Spira, A.; Yu, E.Y.; Burke, J.M.;
Shaffer, D.; et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line
treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three arm, randomized
controlled phase II trial. J. Clin. Oncol. 2016, 34, 1500–1509. [CrossRef]
65. Petrylak, D.P.; de Wit, R.; Chi, K.N.; Drakaki, A.; Sternberg, C.N.; Nishiyama, H.; Castellano, D.; Hussain, S.;
Fléchon, A.; Bamias, A.; et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with
locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): A randomised,
double-blind, phase 3 trial. Lancet 2017, 390, 2266–2277. [CrossRef]
66. Apolo, A.B.; Mortazavi, A.; Stein, M.N.; Davarpanah, N.N.; Nadal, R.M.; Parnes, H.L.; Ning, Y.M.;
Francis, D.C.; Cordes, L.M.; Berniger, M.A.; et al. A phase I study of cabozantinib plus nivolumab (CaboNivo)
and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial
carcinoma (UC) and other genitourinary (GU) tumors. J. Clin. Oncol. 2017, 35, e4562. [CrossRef]
67. US National Library of Medicine. A Study of Avelumab in Combination with Axitinib in Non-Small Cell
Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF). Available online: https://clinicaltrials.
gov/ct2/show/NCT03472560 (accessed on 19 October 2019).
68. Hahn, N.M.; Stadler, W.M.; Zon, R.T.; Waterhouse, D.; Picus, J.; Nattam, S.; Johnson, C.S.; Perkins, S.M.;
Waddell, M.J.; Sweeney, C.J.; et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line
therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 2011, 29,
1525–1530. [CrossRef] [PubMed]
69. US National Library of Medicine. Gemcitabine Hydrochloride and Cisplatin with or Without Bevacizumab
in Treating Patients with Advanced Urinary Tract Cancer. Available online: https://clinicaltrials.gov/ct2/
show/NCT00942331 (accessed on 19 October 2019).
70. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.C.; Yu, P.W.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.;
et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis,
angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10, 2298–2308. [CrossRef] [PubMed]
71. Maia, M.C.; Agarwal, N.; McGregor, B.A.; Vaishampayan, U.N.; Choueiri, T.K.; Green, M.C. Phase 1b trial of
cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial
carcinoma (UC) or renal cell carcinoma (RCC). J. Clin. Oncol. 2018, 36, e5. [CrossRef]
72. US National Library of Medicine. Apatinib with Pembrolizumab in Previously Treated Advanced
Malignancies (APPEASE). Available online: https://clinicaltrials.gov/ct2/show/NCT03407976 (accessed
on 10 October 2019).
73. Vanneman, M.; Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev.
Cancer 2012, 12, 237–251. [CrossRef]
74. Siefker-Radtke, A.O.; Necchi, A.; Park, S.H.; GarcÃa-Donas, J.; Huddart, R.A.; Burgess, E.F.; Fleming, M.T.;
Rezazadeh, A.; Mellado, B.; Varlamov, S.; et al. First results from the primary analysis population of the
phase 2 study of erdafitinib (ERDA.; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial
carcinoma (mUC) and FGFR alterations (FGFRalt). J. Clin. Oncol. 2018, 36, e4503. [CrossRef]
75. Gavine, P.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.;
Baker, D.; Mellor, M.J.; et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast
growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72, 2045–2056. [CrossRef]
76. Joerger, M.; Cassier, P.; Penel, N.; Cathomas, R.; Richly, H.; Schostak, M. Rogaratinib treatment of patients
with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. J. Clin. Oncol. 2018,
36, e6. [CrossRef]
Cancers 2020, 12, 192 20 of 22
77. Siefker-Radtke, A.O.; Currie, G.; Abella, E.; Vaena, D.A.; Kalebasty, A.R.; Curigliano, G.; Tupikowski, K.;
Andric, Z.G.; Lugowska, I.; Kelly, W.K.; et al. Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in
combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J. Clin.
Oncol. 2019, 37, 4511. [CrossRef]
78. Morrison, K.; Challita-Eid, P.M.; Raitano, A.; An, Z.; Yang, P.; Abad, J.D.; Liu, W.; Lortie, D.R.; Snyder, J.T.;
Capo, L.; et al. Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new
urothelial cancer biomarker. Mol. Cancer Ther. 2016, 15, 1301–1310. [CrossRef] [PubMed]
79. Petrylak, D.P.; Heath, E.; Sonpavde, G.; George, S.; Morgans, A.; Eigl, B.J.; Picus, J.; Cheng, S.; Hotte, S.J.;
Gartner, E.; et al. Interim analysis of a phase 1 dose escalation trial of the antibody drug conjugate (ADC)
AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Ann. Oncol. 2016, 27, e780.
[CrossRef]
80. Petrylak, D.P.; Perez, R.; Zhang, J.; Smith, D.; Ruether, J.; Sridhar, S.S.; Sangha, R.S.; Lang, J.M.; Heath, E.I.;
Merchan, J.R.; et al. A phase I study of enfortumab vedotin (ASG-22CE.; ASG-22ME): Updated analysis of
patients with metastatic urothelial cancer. J. Clin. Oncol. 2017, 35, e106. [CrossRef]
81. Rosenberg, J.; Sridhar, S.S.; Zhang, J.; Smith, D.; Ruether, J.; Flaig, T.; Baranda, J.C.; Lang, J.M.; Plimack, E.R.;
Sangha, R.S.; et al. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with
metastatic urothelial cancer (mUC). J. Clin. Oncol. 2018, 36, e4504. [CrossRef]
82. Hoimes, C.J.; Petrylak, D.P.; Flaig, T.W.; Carret, A.S.; Melhem-Bertrandt, A.; Rosenberg, J.E. EV-103 study:
A phase 1b dose-escalation and dose expansion study of enfortumab vedotin in combination with immune
checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial
cancer. J. Clin. Oncol. 2018, 36, TPS532. [CrossRef]
83. Bajorin, D.F.; Sharma, P.; Quinn, D.I.; Plimack, E.R. Phase 2 trial results of DN24-02, a HER2-targeted
autologous cellular immunotherapy in HER2+urothelial cancer patients (pts). J. Clin. Oncol. 2016, 34, e4513.
[CrossRef]
84. US National Library of Medicine. Vaccine Therapy with or without Sirolimus in Treating Patients with
NY-ESO-1 Expressing Solid tumors. Available online: https://clinicaltrials.gov/ct2/show/NCT01522820
(accessed on 10 October 2019).
85. Derré, L.; Cesson, V.; Lucca, I.; Cerantola, Y.; Valerio, M.; Fritschi, U.; Vlamopoulos, Y.; Burruni, R.; Legris, A.S.;
Dartiguenave, F.; et al. Intravesical Bacillus Calmette Guerin combined with a cancer-vaccine increases
local T-cell responses in non-muscle-invasive bladder cancer patients. Clin. Cancer Res. 2017, 23, 717–725.
[CrossRef]
86. Sanford, T.; Donahue, R.; Jochems, C.; Dolan, R.; Bellfield, S.; Anderson, M.; Singer, E.; Weiss, R.; Elsamra, S.;
Jang, T.; et al. Immunologic response to a therapeutic cancer vaccine (PANVAC): Initial results from a
randomized phase 2 clinical trial (abstract MP15-10). J. Urol. 2017, 197, e174. [CrossRef]
87. Morse, M.A.; Chapman, R.; Powderly, J.; Blackwell, K.; Keler, T.; Green, J.; Riggs, R.; He, L.Z.; Ramakrishna, V.;
Vitale, L.; et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor
stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 2011, 17, 4844–4853.
[CrossRef]
88. Sharma, P.; Bajorin, D.; Jungbluth, A.; Herr, H.; Old, L.; Gnjatic, S. Immune responses detected in urothelial
carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J. Immunother. 2008, 31,
849–857. [CrossRef]
89. Ahmad, S.; Lam, T.B.; N’Dow, J. Significance of MUC1 in bladder cancer. BJU Int. 2015, 115, 161–162.
[CrossRef] [PubMed]
90. D’Costa, J.J.; Goldsmith, J.C.; Wilson, J.S.; Bryan, R.T.; Ward, D.G. A systematic review of the diagnostic and
prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer 2016, 2, 301–317.
[CrossRef] [PubMed]
91. US National Library of Medicine. A Study of the CDX-1307 Vaccine Regimen in Patients With Newly
Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study). Available online: https://clinicaltrials.
gov/ct2/show/NCT01094496 (accessed on 10 October 2019).
92. Dudley, M.E.; Wunderlich, J.R.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Restifo, N.P.; Royal, R.E.; Kammula, U.;
White, D.E.; Mavroukakis, S.A.; et al. Adoptive cell transfer therapy following non-myeloablative but
lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin.
Oncol. 2005, 23, 2346–2357. [CrossRef] [PubMed]
Cancers 2020, 12, 192 21 of 22
93. Sherif, A.; Hasan, M.N.; Radecka, E.; Rodriguez, A.L.; Shabo, S.; Karlsson, M.; Schumacher, M.C.; Martis, P.;
Winqvist, O. Pilot study of adoptive immunotherapy with sentinel node- derived Tcells in muscle-invasive
urinary bladder cancer. Scand. J. Urol. 2015, 49, 453–462. [CrossRef]
94. Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.;
Lacey, S.F.; et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med.
2014, 371, 1507–1517. [CrossRef]
95. Porter, D.L.; Levine, B.L.; Kalos, M.; Bagg, A.; June, C.H. Chimeric antigen receptor-modified T cells in
chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365, 725–733. [CrossRef]
96. Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.;
Wright, J.F.; et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med.
2013, 368, 1509–1518. [CrossRef]
97. Lamers, C.H.; Sleijfer, S.; van Steenbergen, S.; van Elzakker, P.; van Krimpen, B.; Groot, C.; Vulto, A.;
den Bakker, M.; Oosterwijk, E.; Debets, R.; et al. Treatment of metastatic renal cell carcinoma with CAIX
CAR-engineered Tcells: Clinical evaluation and management of on-target toxicity. Mol. Ther. 2013, 21,
904–912. [CrossRef]
98. Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of a serious
adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing
ERBB2. Mol. Ther. 2010, 18, 843–851. [CrossRef]
99. Kitano, S.; Nakayama, T.; Yamashita, M. Biomarkers for immune checkpoint inhibitors in melanoma. Front.
Oncol. 2018, 8, e270. [CrossRef]
100. Balar, A.V.; Loriot, Y.; Perez-Gracia, J.L.; Hoffman-Censits, J.H.; Petrylak, D.P.; Van Der Heijden, M.S.; Ding, B.;
Shen, X.; Rosenberg, J.E. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally
advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. J. Clin.
Oncol. 2018, 36, e4523. [CrossRef]
101. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.;
Ho, T.S.; et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer. Science 2015, 348, 124–128. [CrossRef] [PubMed]
102. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.;
Luber, B.S.; et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017, 357, 409–413. [CrossRef] [PubMed]
103. Havel, J.J.; Chowell, D.; Chan, T.A. The evolving landscape of biomarkers for checkpoint inhibitor
immunotherapy. Nat. Rev. Cancer 2019, 19, 133–150. [CrossRef]
104. Chan, T.A.; Yarchoan, M.; Jaffee, E.; Swanton, C.; Quezada, S.A.; Stenzinger, A.; Peters, S. Development of
tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann. Oncol. 2019,
30, 44–56. [CrossRef]
105. Urun, Y.; Leow, J.J.; Fay, A.P.; Albiges, L.; Choueiri, T.K.; Bellmunt, J. ERCC1 as a prognostic factor for survival
in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review
and meta-analysis. Crit. Rev. Oncol. Hematol. 2017, 120, 120–126. [CrossRef]
106. Bellmunt, J.; Paz-Ares, L.; Cuello, M.; Cecere, F.L.; Albiol, S.; Guillem, V.; Gallardo, E.; Carles, J.; Mendez, P.;
de la Cruz, J.J.; et al. Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel
prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol.
2007, 18, 522–528. [CrossRef]
107. Teo, M.Y.; Bambury, R.M.; Zabor, E.C.; Jordan, E.; Al-Ahmadie, H.; Boyd, M.E.; Bouvier, N.; Mullane, S.A.;
Cha, E.K.; Roper, N.; et al. DNA damage response and repair gene alterations are associated with improved
survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res. 2017, 23,
3610–3618. [CrossRef]
108. Champiat, S.; Dercle, L.; Ammari, S.; Massard, C.; Hollebecque, A.; Postel-Vinay, S.; Chaput, N.; Eggermont, A.;
Marabelle, A.; Soria, J.C.; et al. Hyperprogressive disease is a new pattern of progression in cancer patients
treated by anti-PD-1/PD-L1. Clin. Cancer Res. 2017, 23, 1920–1928. [CrossRef]
109. Wang, Q.; Gao, J.; Wu, X. Pseudoprogression and hyperprogression after checkpoint blockade. Int.
Immunopharmacol. 2018, 58, 125–135. [CrossRef]
Cancers 2020, 12, 192 22 of 22
110. Soria, F.; Beleni, A.I.; D’Andrea, D.; Resch, I.; Gust, K.M.; Gontero, P.; Shariat, S.F. Pseudoprogression and
hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J.
Urol. 2018, 36, 1703–1709. [CrossRef] [PubMed]
111. Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litière, S.; Dancey, J.;
Chen, A.; et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet
Oncol. 2017, 18, 143–152. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
